Breast cancer is a heterogeneous disease, and accurate determination of basic biomarkers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is crucial for selecting appropriate treatment for breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.